An all-oral regimen of selinexor + pomalidomide + low-dose dexamethasone appears to be safe and highly active in patients with heavily pretreated MM, warranting further evaluation.
Initial results from ongoing phase I study suggest CC-93269 is safe with promising dose-dependent activity in heavily pretreated multiple myeloma.
The BCMA-directed CAR T-cell therapy JNJ-4528 demonstrated manageable safety profile and robust efficacy in heavily pretreated patients with R/R MM.
Long-term follow-up of LEGEND-2 suggests LCAR-B38M CAR T-cell therapy highly active in patients with relapsed/refractory multiple myeloma.
The addition of daratumumab to VRd in transplant-eligible patients with MM led to significant improvement in response that deepened over time vs VRd alone.
PET-negative findings at baseline portend a favorable prognosis for patients with newly diagnosed MM, as does PET and MRD double negativity postconsolidation after D-VTd and transplantation.
Results from phase III study suggest no significant PFS improvement from addition of clarithromycin to Rd in newly diagnosed, transplant-ineligible patients with myeloma.
Interim results from ongoing phase II study suggest ixazomib/daratumumab/dexamethasone effective in unfit or frail patients with newly diagnosed myeloma.
Responses to KRd followed by ASCT, KRd consolidation, and Rd maintenance therapy associated with improved depth of response in smoldering MM.
Daratumumab plus VMP demonstrates significant PFS, OS improvements vs VMP alone in transplantation-ineligible patients with newly diagnosed multiple myeloma.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone effective with rapid and deep responses in newly diagnosed multiple myeloma.
The addition of daratumumab to triplet IRd induction therapy with modified-dose dexamethasone was associated with rapid responses that deepened over time.
In patients with R/R MM, the combination of venetoclax/daratumumab/dexamethasone, with or without bortezomib, showed an acceptable safety profile and promising response rate.
Initial findings from this preliminary study indicate that combined treatment with venetoclax and dexamethasone is safe and active in patients with t(11;14) R/R MM.
The phase III CANDOR trial demonstrated significant PFS benefit with carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.